What is Zacks Research’s Forecast for Moderna Q2 Earnings?

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Zacks Research dropped their Q2 2025 EPS estimates for shares of Moderna in a note issued to investors on Wednesday, May 21st. Zacks Research analyst S. Ganoria now expects that the company will post earnings of ($3.26) per share for the quarter, down from their previous forecast of ($3.10). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Zacks Research also issued estimates for Moderna’s Q3 2025 earnings at ($2.09) EPS, Q4 2025 earnings at ($2.67) EPS, Q1 2026 earnings at ($2.26) EPS, Q2 2026 earnings at ($2.84) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.54) EPS, FY2026 earnings at ($8.18) EPS, Q1 2027 earnings at ($1.88) EPS and FY2027 earnings at ($4.43) EPS.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. During the same period in the prior year, the firm posted ($3.07) EPS. The firm’s revenue was down 35.3% compared to the same quarter last year.

Several other equities analysts have also recently commented on MRNA. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Morgan Stanley decreased their target price on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Royal Bank of Canada decreased their target price on shares of Moderna from $32.00 to $28.00 and set a “sector perform” rating for the company in a report on Friday, May 2nd. Bank of America decreased their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Finally, Evercore ISI decreased their target price on shares of Moderna from $50.00 to $32.00 and set an “in-line” rating for the company in a report on Friday, May 2nd. Four investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $53.58.

Moderna Stock Down 1.7%

MRNA stock opened at $26.26 on Monday. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $164.73. The firm’s 50-day simple moving average is $27.08 and its 200 day simple moving average is $34.39. The stock has a market cap of $10.16 billion, a PE ratio of -2.83 and a beta of 1.99.

Institutional Trading of Moderna

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the 1st quarter valued at about $25,000. SVB Wealth LLC bought a new stake in shares of Moderna in the 1st quarter valued at about $28,000. Costello Asset Management INC bought a new stake in shares of Moderna in the 1st quarter valued at about $30,000. Sentry Investment Management LLC bought a new stake in Moderna during the 1st quarter worth approximately $31,000. Finally, Deseret Mutual Benefit Administrators increased its stake in Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company’s stock worth $32,000 after purchasing an additional 392 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.